News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 210
- Sources here
- 21
- Companies here
- 9
Active search
210 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Helmerich & Payne (HP) Reports Q2: Everything You Need To Know Ahead Of Earnings
Helmerich & Payne (NYSE: HP) is set to announce its Q2 earnings this Wednesday after market close. The company missed revenue expectations last quarter, and analysts are projecting a 5.7% year-on-year revenue decline for the upcoming quarter. Despite past misses, investor sentiment in the …
Helmerich & Payne, Inc. (NYSE: HP) CFO has 2,150 shares withheld
Helmerich & Payne, Inc. CFO Todd N. Scruggs reported a non-market disposition of 2,150 common shares, which were withheld at $34.57 per share to cover an exercise price or tax liability. Following this transaction, Scruggs directly holds 39,981 common shares. This insider transaction was …
The Elmet Group Co. Schedules Second Quarter 2026 Earnings Call
The Elmet Group Co. (ELMT) announced its second quarter 2026 earnings call, scheduled for Thursday, August 13, 2026, at 9:00 a.m. Eastern Time. Management will discuss financial results for the quarter ending June 30, 2026, followed by a Q&A session. A press release with …
Elmet Group Sets Aug. 13 Call to Discuss Second-Quarter Results
The Elmet Group (NASDAQ: ELMT) has scheduled a conference call and webcast for August 13, 2026, at 9:00 a.m. Eastern Time, to discuss its second-quarter 2026 financial results. A detailed earnings press release will precede the call, which will include a Q&A session with …
ETFs Investing in Elme Communities Stocks
This article lists several ETFs that invest in Elme Communities (ELME) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM for each fund. It aims to help investors find accessible and lower-risk opportunities to invest in ELME through …
Elme Communities 3Q 2025: Revenue $62.1M, EPS $(0.04) — 10-Q Summary
Elme Communities reported its third-quarter 2025 financial results, showing real estate rental revenue of $62.1 million and a net loss of $3.57 million, leading to a diluted EPS of $(0.04). The company is currently undergoing a plan of sale and liquidation, having sold six …
Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth
Relmada Therapeutics has announced the appointment of Bipin Dalmia as its new Chief Business Officer. In this role, Dalmia will be responsible for leading business development strategies to advance the company's lead asset, NDV-01, and drive overall corporate growth. His appointment is expected to …
Janus Henderson Group PLC Increases Position in Relmada Therapeutics, Inc. $RLMD
Janus Henderson Group PLC significantly increased its stake in Relmada Therapeutics (NASDAQ:RLMD) by 52.2% in the first quarter, now owning over 11 million shares, representing 10.55% of the company. Institutional investors collectively hold 45.24% of RLMD, and analysts have a "Moderate Buy" rating with …
Elme Communities Revenue Breakdown – NYSE:ELME
The article provides a brief financial overview for Elme Communities (NYSE: ELME) on TradingView, listing its stock exchange information and indicating that market data is provided by ICE Data Services and FactSet. It primarily focuses on navigating the financial data available for ELME on …
GEG|Great Elm Group Inc|Price:2.150|Chg%:-0.050
Great Elm Group Inc (GEG) has a current stock price of $2.240, experiencing a 4.19% increase. The company's fundamentals are considered healthy with good growth potential, though its valuation is seen as fairly valued within its industry. Analysts currently rate GEG as a "Hold," …
Elme Communities (NYSE: ELME) advances liquidation, targets late‑2026 wind‑down
Elme Communities (NYSE: ELME) is progressing with its shareholder-approved Plan of Sale and Liquidation, reporting net assets of $167.7 million as of June 30, 2026. The company has sold several properties, paid a special liquidating distribution of $14.67 per share in January 2026, and …
4 Energy Stocks That Could Surpass Q2 Earnings Estimates
The article identifies four energy stocks—Calumet (CLMT), Western Midstream Partners (WES), Helmerich & Payne (HP), and Transocean Ltd. (RIG)—that are poised to exceed Q2 earnings estimates. This positive forecast is attributed to a strong commodity-price environment, disciplined spending, and improved operating conditions in the …
Great Elm Capital Corp (GECC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Great Elm Capital Corp (GECC), stating its current valuation score is 7.65, placing it 13th out of 25 in the Collective Investments industry. It notes GECC's current P/E ratio is -1.93, significantly below its recent high and …
Helmerich & Payne (HP) Expected to Beat Earnings Estimates: Should You Buy?
Helmerich & Payne (HP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results …
Great Elm Group Inc (GEG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Great Elm Group Inc (GEG) by business segment, including Equipment Sales, Medical Equipment Rental Income, and Service Revenues. The data, updated as of March 3, 2025, shows that Equipment Sales constitute the largest proportion of revenue. …
Relmada Therapeutics Inc (RLMD) Financial Health: Profitability & Balance Sheet Analysis
Relmada Therapeutics Inc (RLMD) currently holds a financial score of 5.49, placing it low within the Biotechnology & Medical Research industry, reflecting weak financial status and low operating efficiency. The report indicates that the company has not yet disclosed relevant data for several key …
Helmerich & Payne Number of Employees 2026 | Employee Count & Headcount Data
Helmerich & Payne (HP) had approximately 15,903 employees worldwide as of March 2026, representing a 1.9% decline from 2023. The company is actively hiring, with 99 active job postings in 2026, a 44.4% increase from 2025. The workforce is concentrated in the United States, …
Helmerich & Payne (HP) Expected to Announce Earnings on Wednesday
Helmerich & Payne (HP) is scheduled to report its Q3 2026 earnings after market close on Wednesday, August 5th, with analysts projecting earnings of $0.11 per share and revenue of $987.7 million. This follows a previous quarter where the company missed expectations, reporting a …
Helmerich & Payne (HP): Buy, Sell, or Hold Post Q1 Earnings?
Helmerich & Payne (HP) has shown significant revenue growth and an improved EBITDA margin, indicating strong operational leverage. However, its low gross margin suggests potential struggles in lower commodity price environments. Despite the mixed signals, the article concludes that the company's merits outweigh its …
With New $250M Deal, Elme Is Fully Set To Liquidate
Elme Communities has secured a new $250 million deal to sell its Riverside Apartments, a 1,222-unit complex in Alexandria, Virginia, to FPA Multifamily LLC. This new agreement comes after a previous $280 million deal fell through, allowing Elme to get back on track with …
Relmada names Bipin Dalmia as chief business officer By Investing.com
Relmada Therapeutics, Inc. has appointed Bipin Dalmia as its new Chief Business Officer. Dalmia brings nearly 30 years of biopharmaceutical experience, having previously led portfolio strategy and business development at Ferring Pharmaceuticals, where he also played a key role in the U.S. launch of …
Relmada names Bipin Dalmia as Chief Business Officer to advance NDV-01 and commercial strategy
Relmada Therapeutics has appointed Bipin Dalmia as its new Chief Business Officer, reporting directly to CEO Sergio Traversa. Dalmia will be responsible for leading corporate strategy, commercial planning, and business development, specifically focusing on the late-stage development of NDV-01. This appointment highlights Relmada's commitment …
Relmada names Bipin Dalmia as chief business officer
Relmada Therapeutics, Inc. has appointed Bipin Dalmia as its new Chief Business Officer. Dalmia, who brings nearly 30 years of biopharmaceutical experience, will be responsible for leading the company’s corporate strategy, commercial planning, and business development initiatives. He previously served at Ferring Pharmaceuticals, where …
Relmada hires executive with U.S. bladder cancer gene therapy experience
Relmada Therapeutics (Nasdaq: RLMD) has appointed Bipin Dalmia, PhD, MBA, as its Chief Business Officer. Dalmia brings nearly 30 years of biopharmaceutical leadership, including experience leading the Uro-Oncology Franchise and the U.S. launch of ADSTILADRIN, the first FDA-approved intravesical gene therapy for BCG-unresponsive non-muscle …